Kornimate/medical-research-clean huggingface dataset:
ultrasound guided paravertebral block versus erector spinae block for postoperative analgesia after inguinal hernia repair in pediatric patients

Conditions: Analgesia, Postoperative

Summary: the aim of the study is to compare postoperative analgesia in pediatric patients undergoing inguinal hernia repair by comparing the efficacy of ultrasound guided paravertebral block versus ultrasound guided erector spinae plane block.

* to assess the total amount of rescue analgesic consumption in the first 24 hours post-operatively in each group. * to measure the time of first request of rescue analgesia and to assess pain intensity at rest (static) and after movement or coughing (dynamic) using 10 points modified objective pain score (mops). * to record the incidence of complications (hematoma, local anesthetic toxicity, pneumothorax, infection, hypotension, epidural or intrathecal spread). * over all parent's satisfaction: the parents will be asked to rate the overall degree of satisfaction of the analgesia by using a 5-points likert-like verbal scale (1 = very dissatisfied analgesia, 2 = dissatisfied analgesia, and 3 = neutral, 4=satisfied analgesia, and 5=very satisfied analgesia).

Eligibility criteria:
inclusion criteria: 1 - parents acceptance 2. age: preschool and school age child (24 months-12 years old). 3. sex: both sex (males or females). 4. physical status: asa 1\& ii. 5. type of operation: elective unilateral inguinal hernia repair exclusion criteria: 1- patient with any contraindications of regional blocks (as coagulopathy or local infection at injection site) 2. patients with known history of allergy to the study drugs (bupivacaine and lidocaine). 3. advanced hepatic, renal, cardiovascular, neurologic and respiratory diseases.

Keywords: postoperative analgesia ultrasound guided paravertebral block ultrasound guided erector spinae plane block inguinal hernia repair in pediatric
postprandial lipemia and glycemia following a high-fat meal

Conditions: Hypercholesterolemia; Postprandial Hyperglycemia; Lipid Disorder

Summary: the goal of this clinical trial is to determine the acute effects on postprandial lipemia and glycemia by supplementing a high-fat meal with either white button (wb) or shiitake (sh) mushroom powder in relatively healthy adults, aged 18 to 35.


Eligibility criteria:
inclusion criteria: * generally healthy * non-diabetic * normal to mildly hypercholesterolemic (total cholesterol 200-239 mg/dl and ldl-c 130-159 mg/dl) * have bmi \<30 or bf% (men \<25%, women \<32%) * no known disease of the liver or gallbladder * no documented problems with fat metabolism * normal lipemic response to a lipid challenge * no known mushroom allergy exclusion criteria: * diabetic * pregnant * bmi \>30 * liver disease * gallbladder disease * mushroom allergy * lipid disorder

Keywords: mushroom lipid metabolism postprandial lipemia postprandial glycemia
transillumination device for peripheral intravenous placement in patients with sickle cell disease (perfid)

Conditions: Sickle Cell Crisis

Summary: the primary goal of this randomized, controlled, open-label study is to determine the efficacy of accuveinv400 (a transillumination veins device) to facilitate peripheral intravenous (ivp) catheter placement during a vaso-oclusive crisis. the investigators hypothesized that the number of attempts to a successful placement of a peripheral iv, our primary outcome, would be shorter with the assistance of the accuvein v400. it is also expected that accuveinv400 will reduce the time of the procedure, the rate of failure, the technique-related pain.


Eligibility criteria:
inclusion criteria: * sickle cell patients (all genotypes) * patients hospitalized for uncomplicated vaso-occlusive crisis (cvo) in internal/general medicine department * patients requiring the placement or replacement of a peripheral intra-venous catheter in the department of internal/general medicine * patients arrived in the internal/general medicine department of the hospital between 9h and 18h and except weekends * signed informed consent. * affiliated to the french health care insurance. exclusion criteria: * signs of shock * acute chest syndrome * central venous catheter already present * indication to have a central venous catheter from the ourset * patient who has already participated to the perfid study during the current hospitalization * refusal of the patient's participation * pregnant or lactating woman * patient under guardianship or curatorship

Keywords: sickle cell crisis intravenous catheter transillumination
pathophysiological mechanisms of fibromuscular dysplasia

Conditions: Fibromuscular Dysplasia

Summary: fibromuscular dysplasia is an non inflammatory non atherosclerotic obstructive arterial disease affecting mid-size arteries. it is considered as a rare vascular disease of unknown origin. fibromuscular dysplasia may become symptomatic depending on location and severity of narrowing of the arterial lumen. for example,when a stenosis develops within a renal artery, arterial hypertension may develop. the cause of fibromuscular dysplasia is unknown. several factors have been suggested to be associated with it: tobacco abuse or oestrogens. in order to progress into identifying possible causative mechanisms of the disease, we design a pathophysiology study destined to assess endothelial function in patients with fibromuscular dysplasia and to identify possible plasmatic biomarkers of the disease.


Eligibility criteria:
inclusion criteria for patients with multifocal fibromuscular dysplasia: * confirmed multifocal fibromuscular dysplasia * diagnosed for less than 10 years * without significant atherosclerotic disease or recent cardiovascular event * statins and antiplatelet drugs are forbidden * hypertensive patients

Keywords: fibromuscular dysplasia endothelium microparticles microrna
development of cv risk prediction tools based on ai and fundus imaging technology study (perfect)

Conditions: Cardiovascular Diseases

Summary: this study aims to develop a cardiovascular disease (cvd) screening tool and cardiovascular risk prediction tool based on fundus imaging data with the method of artificial intelligence.

this study will establish a cohort of individuals including patients with cvd and participants with high cvd risk, and all the study participants will be follow-up for 1 year. by collecting baseline clinical data, fundus imaging data, and cvd events during the follow up, this study aims to distinguish cvd status based on the fundus imaging data, and explore the association between fundus imaging data and occurence of cvd during the follow up. by using machine learning approach, this study aims to construct a cvd screening tool and cvd prediction tool based on fundus imaging data.

Eligibility criteria:
inclusion criteria: three types of participants will be included, which are: * participants with established coronary heart disease, including previously diagnosed myocardial infarction, previous treatment with coronary intervention or coronary artery bypass grafting, coronary artery stenosis ≥50%, or chest pain with objective evidence of myocardial ischemia (myocardial ischemia indicated by stress electrocardiogram or stress imaging) * participants with established stroke. * participants without coronary heart disease or stroke, but are at high risk for cvd, defined as meeting at least two of the following: 1. men aged ≥ 60 years old, or women aged ≥ 65 years old; 2. diabetes; 3. total cholesterol\>5.2 mmol/l, or ldl-c\>3.4 mmol/l, or hdl-c\<1.0 mmol/l; 4. currently smoking, defined as daily smoking lasting for 1 year or more. exclusion criteria: * participants unable to provide fundus imaging data required for the study due to the following reasons: 1. permanent blindness, blurred vision, flying mosquito disease, or refractive medium opacity seriously affecting fundus examination, such as severe cataracts, vitreous hemorrhage, etc. 2. macular edema, severe nonproliferative retinopathy in diabetes, proliferative vitreoretinopathy, radiation ophthalmopathy or retinal vein occlusion 3. eyeball enucleation, eye deformities, etc. 4. previous retinal laser therapy, injection therapy for any eye, or history of retinal surgery 5. photosensitivity, or taking medication that can cause photosensitivity, or currently undergoing photodynamic therapy 6. unable to cooperate with examination for collection of fundus imaging data 7. other situations that the participants fail to provide fundus imaging data required for the study * suffering from other serious diseases with an expected survival period of less than one year, such as advanced malignant tumors * unable to adhere to follow-up * other conditions which the researchers consider inappropriate for participants to enroll in the study

Keywords: cardiovascular risk prediction fundus imaging
granulocyte-macrophage colony-stimulating factor, interferon and interleukin-2 as adjuvant treatment for renal cancer

Conditions: Renal Cell Carcinoma

Summary: this prospective study assesses toxicity and potential efficacy of granulocyte-macrophage colony-stimulating factor (gm-csf), interferon (ifn) alpha and interleukin-2 (il-2) postoperatively in patients with high-risk renal cell carcinoma (rcc).

patients with high-risk rcc have a dismal prognosis. to date, no effective adjuvant therapy exists for this patients category. we suggest that combination of granulocyte-macrophage colony-stimulating factor (gm-csf), interferon alpha (ifn) and interleukin-2 (il-2) stimulate immune system from dendritic cells till cytotoxic t-lymphocytes step by step and eliminate residuary tumor cells. this prospective, non-randomized, phase ii trial assessed low-dose gm-csf, ifn and il-2 postoperatively in patients with high-risk renal cell carcinoma.

Eligibility criteria:
inclusion criteria: * completely resected advanced high-risk rcc * t3b-c, t4, or n1-2, or m1 disease resected to no evidence of disease (ajcc-tnm, 2002) patients must have recovered from any effects of surgery, which must have been - excellent performance status (eastern cooperative oncology group performance status of 0 or 1); * adequate organ function defined as wbc count 4,000/µl, platelet count 100,000/µl, hemoglobin 10 g/dl, serum creatinine 1.5 mg/dl or creatinine clearance 60 ml/min, and direct bilirubin 1.5 mg/dl; and forced expiratory volume at 1 second more than 2.0 l or 75% of predicted for height and age from pre-enrollment pulmonary function testing * age 18 years and older exclusion criteria: * history or evidence of cardiac disease on ecg or autoimmunity * prior systemic treatment for rcc * history of invasive malignancy in the past 5 years or human immunodeficiency virus positivity * positive pregnancy test

Keywords: kidney cancer renal cell carcinoma high risk adjuvant therapy
ketamine and lidocaine infusion in refractory chronic migraine

Conditions: Refractory Chronic Migraine

Summary: ketamine and lidocaine infusion for refractory chronic migraine: comparative study


Eligibility criteria:
inclusion criteria: * all participants must fulfill the following inclusion criteria 1. medically stable outpatients with confirmed diagnosis of refractory chronic migraine according to american headache society 2. are reliable and willing to make themselves available for the duration of the study and are willing to follow up. 3. men or women older than 18years of age. 4. clear written informed consent from each participant in the trial. 5. adult patients with refractory migraine or refractory chronic migraine defined according to the american headache society exclusion criteria: 1. pregnancy, active psychosis, liver disease, uncontrolled cardiac disease or cardiac rhythm abnormalities 2. presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study 3. participation in any other type of medical research that may interfere with the interpretation of the study. 4. patients with hemocoagulation disorders, local infection or those who refused to consent
longitudinal data registry of plasma cell dyscrasia

Conditions: Multiple Myeloma and Other Plasma Cell Neoplasms

Summary: this study aims to identify clinical characteristics, response and clinical outcome of plasma cell dyscrasia (pcd) diagnosed in zhongshan hospital, fudan university from may 2023. in its current version, the registry incorporates historical data (collected from 2007) and is prospectively collecting follow-up data and recording patient outcomes.

pcd is a spectrum of diseases that is being gradually understood in asia. this study aims to observe and describe the clinical and genetic characteristics of chinese pcd patients, and to explore the relationship between the characteristics and pathogenesis. it also aims to discover the potential distinct clonal evolution patterns among different subtype of this disease spectrum. this study is a non-interventional real-world, study. alll registered data are collected from real clinical practice cases. the medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.

Eligibility criteria:
inclusion criteria: patients with pathological diagnosis of pcd \[e.g.: symptomatic/asymptomatic multiple myeloma, monoclonal gammopathy of undetermined significance (mgus), poems syndrome, light chain (al) amyloidosis) from 2007 to 2027 in zhonshan hospital. patients who had complete diagnostic, treatment and follow-up records. with fully comprehension and signature of the informed consent form (icf) for participation. exclusion criteria: patients who refused to use reliable methods of contraception during pregnancy, lactation or age-appropriate period. patients who suffered from severe mental illness. patients who were deemed unsuitable for inclusion by the investigator.
three intraocular lenses designed to improve distance, intermediate and near vision following lens extraction

Conditions: Cataract

Summary: the objective of this study is to compare the contrast sensitivity, high and low contrast visual acuity (va), glare meter outcomes, and subject satisfaction with three different fda-approved intraocular lenses (iols) designed to improve distance, intermediate, and near vision following lens extraction in adults at least 40 years of age.


Eligibility criteria:
inclusion criteria: * subjects must be undergoing primary iol implantation for the correction of aphakia following continuous curvilinear anterior capsulotomy and phacoemulsification cataract extraction. * subjects must require a spherical lens power from 10.00 diopters (d) to 33.00 d. * subjects must have the potential for corrected distance visual acuity (cdva) of 20/32 or better in both eyes. * subjects must have stopped contact lens wear for at least two weeks for soft lens wearers or three weeks for gas permeable lens wearers prior to biometry and surgery. * at the time of surgery, subjects must have an intact centered capsulorhexis, intact posterior capsule, and no zonular rupture. * subjects must have ≤ 1.25 d of preoperative corneal astigmatism in both eyes. exclusion criteria: * subjects with diagnoses of degenerative visual disorders (eg, macular degeneration, or other retinal disorders) that cause potential acuity losses to a level of 20/32 or worse. * subjects with conditions with increased risk of zonular rupture, such as pseudoexfoliation syndrome. * subjects who have any active inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjunctivitis, and keratouveitis. * subjects with uncontrolled glaucoma. * subjects with previous retinal detachment. * subjects with visually significant diabetic retinopathy (proliferative or nonproliferative) which reduces potential acuity to 20/32 or worse. * subjects with rubella, bilateral congenital, traumatic, complicated or polar cataract. * subjects with marked microphthalmos or aniridia. * subjects who have had previous corneal surgery. * subjects with irregular corneal astigmatism. * subjects with amblyopia which reduces potential acuity to 20/32 or worse. * subjects with optic atrophy. * subjects with iris neovascularization. * subjects with clinically significant retinal pigment epithelium/macular changes which reduces potential acuity to 20/32 or worse. * subjects with chronic use of systemic steroids or immunosuppressive medications.

Keywords: phacoemulsification intraocular lens
neoadjuvant endocrine therapy in er-positive, her2-negative early stage breast cancer

Conditions: Breast Cancer; HER2-negative Breast Cancer; Node-negative Breast Cancer; Breast Carcinoma

Summary: the goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.


Eligibility criteria:
inclusion criteria: * pathologically confirmed invasive breast cancer, clinically stage i-ii. * clinically lymph node negative * eligible for anti-endocrine treatment (per medical oncologist) * postmenopausal women * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * progesterone receptor negativity * high grade tumor * synchronous non-breast malignancy * receiving any other investigational agents that could impact the efficacy of this trial regimen * history of allergic reactions attributed to compounds of similar chemical or biologic composition to anastrozole, letrozole, exemestane, tamoxifen or other agents used in study * uncontrolled intercurrent illness * medical, psychiatric or other condition and/or social situations that would limit compliance with study requirements

Keywords: neoadjuvant endocrine therapy early stage
biomarker expression in tissue samples from patients with bone sarcomas

Conditions: Localized Osteosarcoma; Metastatic Osteosarcoma; Recurrent Osteosarcoma

Summary: this trial studies biomarker expression in tissue samples from patients with bone sarcomas. studying biomarker in tissue samples from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer

study subtype: ancillary/correlative observational study model: case-only time perspective: retrospective biospecimen retention: samples without dna biospecimen description: tissue samples obtained from cooperative human tissue network (chtn) study population description: patients enrolled on p9754 and aost0121 clinical trials sampling method: non-probability sample primary objectives: i. to determine if there is differential expression of tumor factor (tf) among patients with osteosarcoma. ii. to determine if there is an association between overall survival and disease free survival and the extent of tf expression. iii. to determine if tf expression correlates with presence of gross metastatic disease at presentation, and development of subsequent metastases. outline: tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.

Eligibility criteria:
inclusion criteria: * tissue samples from patients with osteosarcomas obtained from the chtn: * p9754 clinical trial for patients with non-metastatic osteosarcoma * aost0121 clinical trial for patients with metastatic or recurrent osteosarcoma
basal instincts: towards better understanding of basal cell function in chronic rhinosinusitis with nasal polyps

Conditions: Chronic Rhinosinusitis With Nasal Polyps; Allergic Rhinitis

Summary: during this project, the investigators want to explore in vitro changes in basal cells and the crosstalk with residing immune cells as potential pathogenic mechanisms in crswnp vs healthy controls by using surgically resected patient samples.

the investigators want to use patient and healthy control samples to study/compare the following aspects in vitro: 1. investigate differences in epithelial and basal cell functions and differentiation characteristics. 2. characterize the differences in epithelial cell populations and gene expression patterns. also include an ar subset, to see if changes are specific for crswnp or more general for type 2 inflammatory disease of the upper airways. 3. investigate basal cell activation via different environmental triggers through tlr stimulation. 4. look at the genetic imprinting of basal cells before and after being exposed to specific triggers. 5. investigate whether the secreted proteins from basal cells are chemotactic for other cell populations. 6. investigate the interaction between basal and regulatory t cells.

Eligibility criteria:
inclusion criteria: * patients over the age of 18 * males and females exclusion criteria: * crswnp * ar * smoker, or \< 1-year ex-smoker * underlying systematic pathology (morbus wegener or churg strauss syndrome for example)
cardiosurgery atrial fibrillation register

Conditions: Atrial Fibrillation

Summary: case af aims to describe the reality of medical care of patients in whom atrial fibrillation is treated by cardiac surgical ablation.

case af aims to describe the reality of medical care of patients in whom atrial fibrillation is treated by cardiac surgical ablation. in particular, the following questions should be answered: * indication: which are the different indications for cardiac surgical ablation in patients with atrial fibrillation? * how often and in which patients the different concepts of surgery and ablation procedures are used? at the same time, how often an intervention at the left atrial appendage is carried out? * safety: how secure is the cardiac surgical ablation of atrial fibrillation (periprocedural, during hospital stay and during the long-term follow up)? * effectiveness: how effectively is the cardiac surgical ablation of atrial fibrillation (procedural success)? how often are af recurrences in the long-term follow up? * what is the concommitant medical treatment after surgical ablation?

Eligibility criteria:
inclusion criteria: * atrial fibrilation * treated by cardiac surgical ablation exclusion criteria: * patient denies participation
a phase i study of aflibercept plus folfiri (irinotecan, 5-fluorouracil, and leucovorin) in chinese patients with advanced solid malignancies

Conditions: Neoplasm Malignant

Summary: primary objective: to assess the safety and pharmacokinetics preliminarily of the dose of intravenous (iv) aflibercept used in western studies in combination with folfiri (irinotecan, 5-fluorouracil, and leucovorin) given intravenously every 2 weeks in chinese patients with solid tumors. secondary objectives: * to make a preliminary assessment of antitumor effects of the combination of folfiri plus aflibercept in patients with measurable disease (recist 1.1). * to evaluate the immunogenicity of iv aflibercept.

total duration of the study per patient is in the range of 17 to 29 weeks. this trial is being conducted in china, where the inn designation for the study molecule is "aflibercept" and this term is therefore used throughout the synopsis. in the us, the us proper name is "ziv-aflibercept".

Eligibility criteria:
inclusion criteria: - histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which folfiri (irinotecan, 5-fluorouracil, and leucovorin) treatment is appropriate exclusion criteria: * treatment with chemotherapy, hormonal therapy, radiotherapy, surgery, or an investigational agent within 28 days * eastern cooperative oncology group (ecog) \>1 * need for a major surgical procedure or radiation therapy during the study * diagnosis of squamous-cell lung cancer * cumulative radiation therapy to \> 25% of the total bone marrow * history of brain metastases * inadequate organ and bone marrow function * uncontrolled hypertension * evidence of clinically significant bleeding diathesis or underlying coagulopathy * prior folfiri treatment but have not been appropriate for safety reasons * patients with known gilbert's syndrome the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.